41 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22656 | ECOG 0 or 1. Life expectancy superior to 6 months. Previously untreated localized gastric or GEJ adenocarcinoma. Adequate organ function. Plan to proceed to surgery following pre-operative chemotherapy. Be willing to provide tissue from a tumor lesion at |
Amelie Deleporte | Multiple | Merck | KEYNOTE-585 | Trial closed for recruitment | A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) | amelie.deleporte@hubruxelles.be | 3 | 3 | |
| 22669 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Merus | MCLA-158-CL01 | Trial open for recruitment | Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22815 | Recurrent or persistent or metastatic tumor | Ahmad Hussein Awada | Multiple | MSD (Merck Sharp & Dohme) | MK-3475-012 | Trial closed | A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22826 | first line, RECIST 1.1 | Alain Hendlisz | Colon | Roche | MO29112 | Trial closed | A multi-centre randomized clinical trial of Biomarker-Driven maintenance treatment for first-line metastatic colorectal cancer (MODUL) | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 28638 | Saude Conde Rita | Esophagus | Innovent Biologics (Suzhou) Co., Ltd. | ORIENT-15 | Trial closed for recruitment | A Multicenter, Double-blind, Randomised Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-line Treatment of Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | 3 | 3 | |||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22774 | Target tumour diameter of ? 2.0 cm (shortest axis) | Alain Hendlisz | pancreas | OncoSil Medical | PanCO | Trial closed | An open label, single arm pilot study of OncoSilTM, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22741 | Clinical/radiological evaluation compatible with stage III colon adenocarcinoma. No prior chemotherapy. |
Alain Hendlisz | Colon | Institut Jules Bordet | PePiTA | Trial closed | A BGDO study PePiTA trial : Preoperative chemosensitivity in adjuvant stage III colon cancer | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 22641 | Biopsy mandatory, neoadjuvant | Alain Hendlisz | Colon | Celyad | SHRINK | Trial closed for recruitment | CELYAD SHRINK : An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer | alain.hendlisz@hubruxelles.be | 1 | 1 | |
| 29375 | Saude Conde Rita | Multiple | Sotio | SN201 | Trial open for recruitment | A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma (Sotio - SN201) | 1/2 | 1 | |||
| 23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22690 | After standard therapy / RECIST 1.1 | Christiane Jungels | Multiple | Transgene S.A. | TG6002.02 | Trial closed | A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors | christiane.jungels@hubruxelles.be | 1/2a | 1 |